Therapeutic immune modulation by stem cell secreted exosomes
AssigneeXON Cells, Inc.
InventorsThomas Ichim, Vladimir Bogin
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.
Claims15
A method of treating a patient comprising the steps of:
- a) extracting endometrial regenerative cells (ERCs);
- b) culturing said ERCs for a sufficient time period, under conditions permissible for exosome production;
- c) collecting exosomes produced by said ERCs;
- d) concentrating said collected exosomes;
- and
- e) administering said concentrated exosomes and said ERCs to said patient,
- wherein said patient has an autoimmune condition selected from the group consisting of:
- diabetes;
- multiple sclerosis;
- rheumatoid arthritis;
- Hashimoto's thyroiditis;
- graft rejection;
- graft versus host disease;
- and systemic lupus erythromatosis.
A method of treating a patient comprising the steps of:
- a) extracting endometrial regenerative cells (ERCs);
- b) culturing said ERCs for a sufficient time period, under conditions permissible for exosome production;
- c) collecting exosomes generated by said ERC population;
- d) concentrating said collected exosomes to at least 1 μg/mL;
- and
- e) administering 1-2 μg of said concentrated exosomes and at least 100,000 of said ERCs to said patient,
- wherein said patient has an autoimmune condition selected from the group consisting of:
- diabetes;
- multiple sclerosis;
- rheumatoid arthritis;
- Hashimoto's thyroiditis;
- graft rejection;
- graft versus host disease;
- and systemic lupus erythromatosis.
A method of treating a patient having an autoimmune condition comprising the steps of:
- a) obtaining endometrial regenerative cells (ERCs);
- b) introducing into said ERCs an antigen, wherein said antigen is present in one or more exosomes produced by said ERCs;
- c) purifying and concentrating said exosomes to at least 1 μg/mL;
- d) administering an amount of said concentrated exosomes and an amount of said ERCs into the patient to suppress a biological pathway associated with an immune pathway associated with the autoimmune condition,
- wherein said autoimmune condition is selected from the group consisting of:
- diabetes;
- multiple sclerosis;
- rheumatoid arthritis;
- Hashimoto's thyroiditis;
- graft rejection;
- graft versus host disease;
- and systemic lupus erythromatosis.
Dependencies are inferred from the claim text.